

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



JAK3 Kinase Domain (human, recombinant)

Item No. 42275

Overview and Properties

Synonyms: Janus-Associated Kinase 3, Leukocyte Janus Kinase, L-JAK, Tyrosine-protein Kinase

Source: Active recombinant human N-terminal His-tagged JAK3 kinase domain expressed in

insect cells (sf9)

Amino Acids: 811-1,124 P52333 **Uniprot No.:** Molecular Weight: 37 kDa

Storage: -80°C (as supplied)

Stability: ≥6 months

≥90% estimated by SDS-PAGE **Purity:**

Supplied in: 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride,


3 mM DTT, 20% glycerol, and 200 mM imidazole

Protein

Concentration: batch specific mg/ml batch specific U/ml Activity: batch specific U/mg Specific Activity:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Inhibition of JAK3 Kinase Domain activity by the inhibitors JAK-IN-6 and staurosporine was measured with Chemi-Verse $^{\text{TM}}$ JAK3 Kinase Assay Kit. Representative data only; not all lots

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

JAK3 is a non-receptor tyrosine kinase that has roles in cytokine signaling and immune cell function. ^{1,2} It is composed of N-terminal FERM and SH2 domains, a regulatory JH2 pseudokinase domain, and a C-terminal kinase domain. ^{2,3} JAK3 is constitutively expressed in natural killer (NK) cells and thymocytes and expressed upon cell activation in T cells, B cells, and monocytes. ⁴ Following cytokine binding to the IL-2 receptor (IL-2R), IL-4R, IL-7R, IL-9R, IL-15R, or IL-21R, JAK3 binds to the γc subunit of the receptor and induces heterodimerization of the receptor subunits and activation of STAT transcription factors. ^{1,2,4} Through activation of these receptors, JAK3-mediated signaling is involved in T cell proliferation, differentiation, and survival, B cell differentiation and function, and macrophage activation, among other activities. ^{1,2} Loss-of-function mutations in JAK3 are associated with autosomal recessive severe combined immunodeficiency disease (SCID), while gain-of-function mutations are associated with immune dysregulation and blood cancers, including myeloproliferative neoplasms, T cell lymphomas and leukemias, NK lymphoma-leukemia, and acute lymphoblastic leukemia. ^{1,5,6} Cayman's JAK3 Kinase Domain (human, recombinant) protein can be used for enzyme activity assays. This protein has a calculated molecular weight of 37 kDa.

References

- 1. Benczik, M. and Gaffen, S.L. The interleukin (IL)-2 family cytokines: Survival and proliferation signaling pathways in T lymphocytes. *Immunol. Invest.* **33(2)**, 109-142 (2004).
- 2. Liongue, C., Ratnayake, T., Basheer, F., et al. Janus kinase 3 (JAK3): A critical conserved node in immunity disrupted in immune cell cancer and immunodeficiency. *Int. J. Mol. Sci.* **25(5)**, 2977 (2024).
- 3. Leonard, W.J. and O'Shea, J.J. Jaks and STATs: Biological implications. *Annu. Rev. Immunol.* **16**, 293-322 (1998).
- 4. Notarangelo, L.D. and Candotti, F. JAK3-deficient severe combined immunodeficiency. *Radiol. Clin. North Am.* **20(1)**, 97-111 (2000).
- 5. Ott, N., Faletti, L., Heeg, M., *et al.* JAKs and STATs from a clinical perspective: Loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences. *J. Clin. Immunol.* **43(6)**, 1326-1359 (2023).
- Philips, R.L., Wang, Y., Cheon, H., et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185(21), 3857-3876 (2022).

[734] 971-3335 FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM